期刊文献+

美国医疗产品安全主动监测系统概述及启示 被引量:10

Medical Product Active Surveillance System in America and Its Revelation
下载PDF
导出
摘要 目的为建立我国药品安全主动监测系统提供思路和参考。方法研究美国医疗产品安全主动监测系统,分析其关键技术和实现方式,为我国建立药品安全主动监测系统提出建议。结果与结论美国医疗产品安全主动监测系统借助通用数据模型、分布式数据库等技术将医疗保险、医院电子健康数据、人口登记等有关电子健康数据进行虚拟整合,并通过特定方法对数据综合分析利用,高效、经济地从真实世界获得医疗产品安全性问题方面的证据。我国可结合国情建立药品安全主动监测系统,作为辅助验证药品安全性问题的新手段。 Objective To provide reference for establishing active surveillance system of drug safety in China. Methods The active surveillance system of medical product safety in United States was studied by analyzing the key technologies and implementation methods, and the recommendations for establishing similar system in China were provided. Results Conclusion The medical product safety active surveillance system in United States uses common data model(CDM), distributed database and other technologies to build virtual database consist of health insurance data, hospital health data, population registration data. The system can analyze and utilize the virtual database through specific methods, get evidence about medical product safety issues from the real world efficiently and economically. We can combine with China's national conditions to establish active surveillance system for drug safety.
出处 《中国药物警戒》 2017年第1期32-35,共4页 Chinese Journal of Pharmacovigilance
关键词 主动监测 药品不良反应 通用数据模型 分布式数据库 active surveillance adverse drug reaction common data model distributed database
  • 相关文献

参考文献7

二级参考文献61

  • 1张亮,王大猷.处方事件监测[J].中国药物警戒,2005,2(1):4-6. 被引量:8
  • 2顾牛范 吴文源.精神药物不良反应监测[J].新药与临床,1985,4(4):228-228.
  • 3曾繁典,施侣元,詹思延,等.药物流行病学教程[M].2008.2-78.
  • 4FDA.the Senate and House of Representatives of the United States of America, Food and Drug Administration Amendments Act of 2007, [EB/OL]. 2007-09[2011-01].http://frwebgate.access.gpo.gov/cgibin/getdoc.cgi?dbname=110 cong_public_laws&docid=f:pub1085. 110.
  • 5FDA Developing the Sentinel System - A National Resource for EvidenceDevelopment [EB/OL]. 2008-03 [2011-01-12]http.//www. fda.gov/Safety/FDAsSentinelInitiative/ucm089474.htm.
  • 6Platt R, Wilson M, Chan K A, et al. The new Sentinel Network -improving the evidence of medical-product safety[J]. N Engl J Med, 2009,361:645-647.
  • 7FDA, The Sentinel Report, National Strategy for Monitoring Medical Product Safety is available at[EB/OL].[ 2008-03[2011-02] http: //www. fda. gov/downloads/S afety/FDAsSentinellnitiative/UCM 124701pdf.
  • 8Brown J S, Holmes J H, Shah K, et al . Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care[J]. Med Care, 2010,48:Suppl:S45-S51.
  • 9Executive Office of the President President' s Council of Advisors on Science and Technology, Realizing the full potential of health information technology to improve healthcare for Americans: the path forward. Washington, DC: Executive Office of the President [EB/OL]. 2010-12[2011 -01].http://www.whitehouse.govlsites/ default/files/microsites/ostp/pcast-health-it-report.pdf.
  • 10Stang PE,Ryan PB,Racoosin JA, et al. Advancing the Sci- ence for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership [ J ]. Ann Intern Med , 2010 ,15 3 : 600-606.

共引文献67

同被引文献88

引证文献10

二级引证文献86

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部